Maymetsi (Metformin Hydrochloride, Sitagliptin)

Metformin hydrochloride lowers blood glucose primarily by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity. Sitagliptin, the second component, blocks the DPP‑4 enzyme, which raises endogenous incretin levels and promotes glucose‑dependent insulin secretion. Together, they provide complementary mechanisms to reduce hyperglycaemia.

The appropriate dose of Maymetsi is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant therapies. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose without medical guidance.

Maymetsi is generally not recommended during pregnancy or lactation unless the potential benefits outweigh the risks. Metformin is sometimes continued in pregnancy under specialist supervision, while sitagliptin lacks sufficient safety data. Clinicians should evaluate each case individually and discuss alternatives when appropriate.

To place an order, submit an enquiry on the Maymetsi product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Maymetsi offers a fixed‑dose combination of a biguanide and a DPP‑4 inhibitor, providing dual mechanisms in a single tablet. Compared with metformin alone, it adds the incretin‑enhancing effect of sitagliptin, which can improve glycaemic control without the weight gain associated with some other agents. It is an alternative to separate tablets or to other combination products such as metformin‑sulfonylurea blends.

Maymetsi tablets should be stored at ambient temperature, preferably below 25 °C, in their original container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Maymetsi is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

The most serious adverse events include lactic acidosis, which is rare but potentially fatal, severe hypoglycaemia especially when combined with insulin or sulfonylureas, and acute pancreatitis. Patients should be educated to recognize symptoms such as unexplained muscle pain, rapid breathing, severe abdominal pain, or persistent nausea and seek immediate medical attention.

Maymetsi is contraindicated in patients with known hypersensitivity to metformin, sitagliptin, or any excipients, as well as those with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and certain hepatic conditions. It should also be avoided in individuals with a history of pancreatitis until the cause is clarified.